Big Pharmas Brexit draws call for anticompetition probe from advocacy groups: report
4.3
来源：
FiercePharma
发布时间：
2025-10-03 11:21
摘要：
U.K. advocacy groups are urging an investigation into potential anticompetitive behavior by major pharmaceutical companies, including Eli Lilly, AstraZeneca, and Merck, who have collectively paused over $2 billion in investments in the U.K. due to unfavorable conditions. The groups allege that these companies are acting in concert to drive up drug prices, raising significant concerns about the investment climate in the U.K. pharmaceutical sector.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
0.5
business_impact
1.0
scientific_rigor
0.0
timeliness_innovation
0.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.0
technical_barrier_competition
0.0
关键证据
U.K. advocacy organizations are pressing for an investigation into suspected anticompetitive behavior.
AstraZeneca, Lilly, and Merck have paused over $2 billion in U.K. investments.
The companies are accused of coordinating actions for anti-competitive purposes.
真实性检查
否
AI评分总结
U.K. advocacy groups are urging an investigation into potential anticompetitive behavior by major pharmaceutical companies, including Eli Lilly, AstraZeneca, and Merck, who have collectively paused over $2 billion in investments in the U.K. due to unfavorable conditions. The groups allege that these companies are acting in concert to drive up drug prices, raising significant concerns about the investment climate in the U.K. pharmaceutical sector.